Litton Mark James
SEC insider (Form 3/4/5 filer). CIK 0001604834. PRESIDENT and CEO at LeonaBio, Inc. (LONA). 17 reported Form 4/5 transactions since Sep 2024; latest on Apr 9, 2026. Located in BOTHELL, WA.
Companies Litton Mark James has filed insider reports for
- LeonaBio, Inc. (LONA): Director, Officer, PRESIDENT and CEO
Litton Mark James
CIK: 0001604834
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LeonaBio, Inc.
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Apr 9, 2026LONA
LeonaBio, Inc.
AwardDirectStock Option (Right to Buy)
750K shares- - Mar 4, 2026LONA
LeonaBio, Inc.
SaleDirect5.2K shares at avg. $5.37$28K - Mar 3, 2026LONA
LeonaBio, Inc.
ExerciseDirect22.3K shares- - Jan 2, 2026ATHA
Athira Pharma, Inc.
SaleDirect2.6K shares at avg. $6.88$18K - Dec 31, 2025ATHA
Athira Pharma, Inc.
ExerciseDirect10.8K shares- - Dec 24, 2025ATHA
Athira Pharma, Inc.
AwardDirectStock Option (Right to Buy)
133.5K shares- - Jul 1, 2025ATHA
Athira Pharma, Inc.
SaleDirect25.1K shares at avg. $0.29$7K - Jun 30, 2025ATHA
Athira Pharma, Inc.
ExerciseDirect108.3K shares- - Mar 3, 2025ATHA
Athira Pharma, Inc.
AwardDirectStock Option (Right to Buy)
333.8K shares- - Mar 3, 2025ATHA
Athira Pharma, Inc.
AwardDirectRestricted Stock Units
222.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 9, 2026 | LONA LeonaBio, Inc. | Award Stock Option (Right to Buy) | 750,000 | - | - | Direct |
| Mar 4, 2026 | LONA LeonaBio, Inc. | Sale | 5,156 | $5.37 | $27,688 | Direct |
| Mar 3, 2026 | LONA LeonaBio, Inc. | Exercise | 22,254 | - | $0 | Direct |
| Jan 2, 2026 |  ATHA Athira Pharma, Inc. | Sale | 2,586 | $6.88 | $17,792 | Direct |
| Dec 31, 2025 | ATHA Athira Pharma, Inc. | Exercise | 10,834 | - | $0 | Direct |
| Dec 24, 2025 | ATHA Athira Pharma, Inc. | Award Stock Option (Right to Buy) | 133,526 | - | - | Direct |
| Jul 1, 2025 | ATHA Athira Pharma, Inc. | Sale | 25,123 | $0.29 | $7,374 | Direct |
| Jun 30, 2025 | ATHA Athira Pharma, Inc. | Exercise | 108,334 | - | - | Direct |
| Mar 3, 2025 | ATHA Athira Pharma, Inc. | Award Stock Option (Right to Buy) | 333,815 | - | - | Direct |
| Mar 3, 2025 | ATHA Athira Pharma, Inc. | Award Restricted Stock Units | 222,543 | - | - | Direct |
1-10 of 17 transactions